Medical Diagnostic Laboratories, L.L.C., (MDL), member of Genesis Biotechnology Group
® (GBG) and CLIA-certified, CAP-accredited laboratory specializing in high-complexity, state-of-the-art, automated DNA-based molecular analyses, launched a new line of testing for the field of Urology. This testing, available through
Uroveda Institute of Urogenital Diseases, an MDL Center of Excellence, blends DNA-based molecular testing with traditional pathology and cytology tests to aid in diagnosing or screening for urologic conditions.
Genesis Biotechnology Group
According to the National Institutes of Health (NIH), medical care costs for urologic diseases in the United States neared $11 billion in 2020. Urologic malignancies such as prostate, bladder, and renal cancers present challenges in diagnoses, treatment decisions, monitoring, and recurrence testing. Prostate, bladder, and renal cancers rank second, seventh, and ninth, respectively, in the top 10 cancers in the US based on new
Genesis Drug Discovery and Development Acquires Integrated Analytical Solutions to Add Off the Shelf PK Profiling Capabilities to Its Portfolio
News provided by
Share this article
® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD
3) announced today that it has acquired the Berkeley-based CRO Integrated Analytical Solutions (IAS). Founded in 2004 and located in the San Francisco bay area, IAS is a GxP-compliant CRO providing bioanalytical, drug metabolism, and analytical chemistry services to clients worldwide.
Integrated Analytical Solutions (IAS) Logo This is our second acquisition in the space of two months as we further expand our presence in the San Francisco bay area, which we see as a market with tremendous growth potential for drug discovery services said Eli Mordechai, Ph.D., Chief Executive Officer (CEO) of GBG. Adding IAS s GxP compliant bioanalytical platform to GD
Genesis Drug Discovery and Development Expands Its Presence in the Clinical Space by Acquiring STATKING Clinical Services
News provided by
Share this article
® (GBG) and its Contract Research Organization (CRO) arm Genesis Drug Discovery & Development™ (GD
3) announced today that it has acquired the Cincinnati-based CRO STATKING Clinical Services. Established in 1989, STATKING provides clinical trial services, including clinical trial management, protocol development, biostatistics, clinical data management, clinical study monitoring, medical writing, medical monitoring, safety reporting, and project management for the regulatory approval of novel drug and medical device products.
STATKING Clinical Services We are very pleased to have STATKING join GBG, and this acquisition demonstrates our commitment to making GD
iPhone被偷，纬创印度厂暴动损失43.7亿卢比，印度梦还好吗？ sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.